To evaluate the efficacy of adjuvant topical dorzolamide–timolol in patients with neovascular age-related macular degeneration unresponsive to anti–vascular endothelial growth factor therapy.
This retrospective, interventional study included 15 patients with neovascular age-related macular degeneration refractory to anti–vascular endothelial growth factor. Patients used topical dorzolamide–timolol twice daily in the neovascular age-related macular degeneration eye and received anti–vascular endothelial growth factor therapy at each visit, with the same fixed interval and agent as before the addition of dorzolamide–timolol. Central macular thickness, maximal subretinal fluid height, and maximal pigment epithelial detachment height were measured at baseline and every visit.
The mean follow-up period was 17.2 ± 5.5 weeks. The mean central macular thickness decreased from 383.5 μm at baseline to 298.3 μm at the final visit (P = 0.041). The mean maximal subretinal fluid height decreased from 105.0 μm at baseline to 58.3 μm at the final visit (P = 0.021). Complete resolution of subretinal fluid was observed in 3 of 11 subretinal fluid–type eyes. There was no significant change in the maximal pigment epithelial detachment height. The mean logarithm of the minimum angle of resolution visual acuity decreased from 0.61 (20/81 Snellen) at baseline to 0.66 (20/91 Snellen) at final visit, which was not significant (P = 0.314). The mean intraocular pressure decreased significantly from 14.9 mmHg at baseline to 12.3 mmHg at the final visit (P = 0.005).
The use of adjuvant topical dorzolamide–timolol was effective in decreasing central macular thickness and subretinal fluid in patients with neovascular age-related macular degeneration refractory to continual fixed-interval intravitreal anti–vascular endothelial growth factor therapy, but did not result in functional improvement in this short-term study.
The use of adjuvant topical dorzolamide–timolol, combined with anti–vascular epithelial growth factor, is effective in decreasing central macular thickness and subretinal fluid height in patients with neovascular age-related macular degeneration refractory to repeated fixed-interval anti–vascular epithelial growth factor injections.
*Department of Ophthalmology, Ewha Womans University School of Medicine, Seoul, Republic of Korea; and
†Department of Ophthalmology, The Institute of Vision Research, Yonsei University College of Medicine, Seoul, Republic of Korea.
Reprint requests: Christopher Seungkyu Lee, MD, Department of Ophthalmology, Yonsei University College of Medicine, Yonsei-ro 50-1, Seodaemu-gu, Seoul, Republic of Korea 03722; e-mail: email@example.com
Supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2016R1D1A1A02937349).
None of the authors has any financial/conflicting interests to disclose.